Annual Review Course (2016)
In preparation for the American Board of Urology (ABU) Qualifying (Part 1) Examination, residents need to have basic urologic knowledge to prepare them for the ABU examinations. To fulfill this need, the American Urological Association (AUA) developed this course to disseminate current urologic knowledge. This course may also be of interest to practicing urologist preparing for the Recertification Examination as well as others, including allied health professionals, looking for a thorough review of basic urologic topics.
Target Audience
- APN/PA
- Resident
- Urologist
Learning Objectives
At the conclusion of this course, participants will be able to:
- Apply basic, generally-accepted urological practices for superior patient care.
- Demonstrate core knowledge of urology necessary for Part I of the American Board of Urology (ABU) qualifying examination and for the recertification examination.
Thursday, June 23, 2016
6:30 a.m. Registration/Breakfast
7:30 a.m. Introduction
Howard B. Goldman, MD and Robert G. Uzzo, MD
PROSTATE CANCER AND BPH
7:45 a.m. Adam S. Kibel, MD
Diagnosis and Screen, Staging, Imaging (including PSA Screening Controversies)
Treatment of Localized Cancer (U.S. Stages A and B), Watchful Waiting, Radiation, Interstitial Irradiation, Surgery, Cryosurgery and Hormonal Therapy)
Treatment of Advanced Cancer (U.S. Stages C and D) and Treatment of Radiation Failure
PEDIATRIC UROLOGY
9:15 a.m. Armando J. Lorenzo, MD
Pediatric Urological Oncology
Wilm’s Tumor and Other Renal Tumors
Rhabdomyosarcoma
Neuroblastoma
Testis Tumors
Andrew J. Kirsch, MD
Pediatric Urinary Incontinence and Bladder Disorders
· Voiding Dysfunction and Neurogenic Bladder
· Developmental Anomalies of the Bladder
· Urinary Tract Infection and Reflux
· Management of Neurogenic and Non-Neurogenic Bladder
10:45 a.m. Break
11:00 a.m. Armando J. Lorenzo, MD
Disorders of the Genitalia
Intersex
Hypospadias
Epispadias-Exstrophy
Undescended Testicle, Hydroceles, Hernias
Andrew J. Kirsch, MD
Congenital Urinary Tract Abnormalities
UPJ Obstruction, UVI Obstruction (megaureter)
Ureteroceles
Cystic Disease
Posterior Urethral Valves
Prune Belly Syndrome
Vesicoureteral Reflux
12:15 p.m. Lunch
1:15 p.m. Pediatric Case Studies
Andrew J. Kirsch, MD and Armando J. Lorenzo, MD
UROLOGIC TRAUMA
2:00 p.m. Allen F. Morey, MD
Renal and Ureteral Trauma: Evaluation and Management
Bladder and Urethral Trauma: Evaluation and Management
Genital Trauma: Evaluation and Management
3:15 p.m. Break
UROLITHIASIS
3:30 p.m. Glenn M. Preminger, MD
Epidemiology, Pathophysiology
Evaluation and Medical Management
4:15 p.m. Peter G. Schulam, MD, PhD
Surgical Management of Stone Disease
LAPAROSCOPY
4:45 p.m. Peter G. Schulam, MD, PhD
Physiology and Complications
5:30 p.m. Meeting Adjourns for the Day
Friday, June 24, 2016
6:30 a.m. Breakfast
FEMALE UROLOGY, URODYNAMICS AND NEUROUROLOGY
7:00 a.m. Stephen R. Kraus, MD
Urodynamics Review
Neurourology
8:00 a.m. Howard B. Goldman, MD
Overactive Bladder/Urgency Incontinence
Stress Urinary Incontinence
Pelvic Organ Prolapse
Vaginal Masses/Urethral Diverticulum
Urinary Fistula
9:15 a.m. Incontinence Case Studies (Panel)
Stephen R. Kraus, MD and Howard B. Goldman, MD
9:30 a.m. Break
RENAL MEDICINE
9:45 a.m. Daniel A. Shoskes, MD
Renal Transplantation
Renal Vascular Disease
Renal Physiology (including Fluid and Electrolytes)
URINARY TRACT INFECTION
11:15 a.m. Duane R. Hickling, MD
12:15 p.m. Lunch
INFECTION AND INFLAMMATION
1:15 p.m. Daniel A. Shoskes, MD
Interstitial Cystitis
Sexually Transmitted Diseases (Gonorrhea, Chlamydia, AIDS and others)
ADRENAL
2:00 p.m. Jay T. Bishoff, MD
Epidemiology, Diagnosis and Imaging (including Cushings, Hyperaldosteronism, Pheochromocytoma, Cancer and the Incidentally Found Adrenal Mass)
Management (including Pheochromocytoma, Cancer, Hyperaldosteronism, Incidentaloma and Metastatic Disease)
2:45 p.m. Break
ANATOMY AND EMBRYOLOGY
3:00 p.m. Howard B. Goldman, MD
Applied Anatomy
Embryology
GU RADIOLOGY
4:45 p.m. Brian R. Herts, MD
Basics of MR, CT and US
Solid and cystic renal masses (CT and MR)
Transitional cell carcinoma
Prostate MR
Adrenal imaging
Scrotal imaging
Retroperitoneal tumors
Radiation basic principles
6:00 p.m. Meeting Adjourns for the Day
Saturday, June 25, 2016
6:30 a.m. Breakfast
PENILE AND URETHRAL CANCER
7:00 a.m. Robert G. Uzzo, MD
Epidemiology
Diagnosis and Staging
Imaging and Treatment
BLADDER CANCER
7:30 a.m. Michael A. O’Donnell, MD
Epidemiology, Anatomy, Diagnosis and Imaging
Treatment of NMIBC/ Superficial Disease Managment
Bladder Cancer test questions
8:30 a.m. Seth P. Lerner, MD, FACS
Staging and risk stratification of muscle invasive bladder cancer
Multidisciplinary treatment including radical cystectomy, lymphadenectomy, peri-operative chemotherapy and chemoradiation therapy
Other bladder sparing treatments
Treatment of metastatic disease
Incontinent and continent urinary diversion techniques
10:00 a.m. Break
RENAL AND URETERAL TUMORS
10:15 a.m. Robert G. Uzzo, MD
Epidemiology, Anatomy, Diagnosis and Imaging (Including Evaluation of Renal Masses)
Treatment of Localized Disease (including Role of Partial Nephrectomy)
Treatment of Metastatic Disease
Transitional Cell Carcinoma
11:30 a.m. Exam Overview, Test Taking Logistics, and ABU Process
J. Christian Winters, MD
12:00 p.m. Lunch
1:00 p.m. AUA Update: Core Curriculum
John P. Mulhall, MD
TESTICULAR TUMORS
1:15 p.m. Wade J. Sexton, MD
Epidemiology, Diagnosis, Staging and Imaging (including the Role of Markers and CIS)
Treatment of Seminoma
Treatment of Non-seminomatous Germ Cell Tumors (including Controversy Regarding Stage A Management, Risk Factors for Recurrence, Algorithms for Stages A,B, and C)
ERECTILE DYSFUNCTION
2:30 p.m. John P. Mulhall, MD
Physiology of Erection, Pathophysiology of Erectile Dysfunction
Evaluation and Management of Erectile Dysfunction
Pathophysiology, Evaluation and Management of Priapism Pathophysiology, Evaluation and Management of Peyronie’s Disease
INFERTILITY
3:30 p.m. Paul J. Turek, MD
Physiology and Pathophysiology of Male Reproduction
Evaluation of the Infertile Male
Treatment of the Infertile Male (Surgical and Non-surgical)
Hypogonadism
Testosterone Replacement
5:00 p.m. Meeting Adjourns for the Day
To hold a reservation, a major credit card number must be provided.
$196 single/double occupancy. Make your reservation online or call 1-800-925-3673. Reference the group code when making your reservation to receive the special group rate. Group Code: ARC
Cut-off Date: Wednesday, June 1, 2016.
Once the AUA group block is full, which may be prior to the cut-off date, the AUA is unable to guarantee rooms at this rate or at this hotel.
Check-in: 3 pm
Check-out: Noon
Glenn M. Preminger, MD | Speaker | Nothing to Disclose | |||
Gary E. Lemack, MD | Speaker | Roivant | Consultant or Advisor | Yes | 11/17/2017 |
Armando J. Lorenzo, MD | Speaker | Nothing to Disclose | |||
Howard B. Goldman, MD | Speaker | Axonics NewUro Galvani | Consultant or Advisor Consultant or Advisor Consultant or Advisor | Yes Yes Yes | 04/04/2017 10/31/2017 01/15/2018 |
Peter G. Schulam, MD | Speaker | Nothing to Disclose | |||
Paul J. Turek, MD | Speaker | Contraline, Inc FutureFamily, Inc | Consultant or Advisor Consultant or Advisor | Yes Yes | 10/18/2017 10/18/2017 |
Andrew Jared Kirsch,M.D. | Speaker | Nothing to Disclose |
Victor W. Nitti, MD | Speaker | Medtronic | Scientific Study or Trial | No | 04/03/2017 |
Daniel A. Shoskes, MD | Speaker | Aquinox | Consultant or Advisor | Yes | 04/03/2017 |
Jay T. Bishoff, MD | Speaker | Nothing to Disclose | |||
Robert G. Uzzo, MD | Speaker | Nothing to Disclose | |||
Michael A. O'Donnell, MD | Speaker | Nothing to Disclose | |||
Seth P. Lerner, MD, FACS | Speaker | Nothing to Disclose | |||
Duane R. Hickling, M.D. | Speaker | Pfizer | Consultant or Advisor,Meeting Participant or Lecturer | Yes | 07/20/2017 |
John P. Mulhall, MD | Speaker | Nothing to Disclose | |||
Stephen R. Kraus, MD | Speaker | Nothing to Disclose | |||
Howard B. Goldman, MD | Speaker | Axonics NewUro Galvani | Consultant or Advisor Consultant or Advisor Consultant or Advisor | Yes Yes Yes | 04/04/2017 10/31/2017 01/15/2018 |
Adam S. Kibel, MD | Speaker | Janssen ConfirmMDx Pfizer | Consultant or Advisor Consultant or Advisor Consultant or Advisor | Yes Yes Yes | 11/12/2017 11/12/2017 03/16/2018 |
Wade Jeffers Sexton , M.D. | Speaker | Nothing to Disclose | |||
Jay Simhan, MD | Speaker | Nothing to Disclose | |||
Brian Herts ,M.D. | Speaker | Siemens Healthineers | Scientific Study or Trial | No | 10/23/2017 |
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this live activity for a maximum of 26.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Available Credit
- 26.25 AMA PRA Category 1 Credit™
- 26.25 Non-Physician Participation